To date, anamorelin, a novel ghrelin receptor agonist, is under clinical evaluation for cachexia treatment because of its ability to improve lean body mass, bodyweight, and in counteracting the anorexia–cachexia symptoms in non–small cell lung carcinoma patients. This evidence concerns the gene GHSR and Cachexia.